within Pharmacolibrary.Drugs.ATC.B;

model B01AC24
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.36,
    Cl             = 0.00017166666666666667,
    adminDuration  = 600,
    adminMass      = 90 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.088,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 2100,            
    Vdp             = 0.11,
    k12             = 22.1,
    k21             = 22.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AC24</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ticagrelor is a direct-acting, oral, reversible P2Y12 receptor antagonist used as an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome or a history of myocardial infarction. Approved for clinical use in many countries including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after single and multiple oral doses.</p><h4>References</h4><ol><li><p>Gelbenegger, G, &amp; Jilma, B (2022). Clinical pharmacology of antiplatelet drugs. <i>Expert review of clinical pharmacology</i> 15(10) 1177–1197. DOI:<a href=\"https://doi.org/10.1080/17512433.2022.2121702\">10.1080/17512433.2022.2121702</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36065676/\">https://pubmed.ncbi.nlm.nih.gov/36065676</a></p></li><li><p>Wang, ZT, et al., &amp; Cai, WM (2020). Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. <i>Journal of food science</i> 85(4) 1285–1291. DOI:<a href=\"https://doi.org/10.1111/1750-3841.15096\">10.1111/1750-3841.15096</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32157685/\">https://pubmed.ncbi.nlm.nih.gov/32157685</a></p></li><li><p>Ma, T, et al., &amp; Li, J (2022). SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor. <i>Frontiers in pharmacology</i> 13 1027627–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2022.1027627\">10.3389/fphar.2022.1027627</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36339534/\">https://pubmed.ncbi.nlm.nih.gov/36339534</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AC24;
